IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer

Area of Science:

• Oncology
• Clinical Trials
• Pharmacology

Background:

• Small cell lung cancer (SCLC) presents a poor prognosis with limited second-line treatment options.
• B7-homolog 3 (B7-H3) is highly expressed in SCLC, making it a potential therapeutic target.
• Ifinatamab deruxtecan (I-DXd) is an antibody-drug conjugate targeting B7-H3, showing promise in various cancers.

Purpose of the Study:

• To evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with relapsed SCLC.
• To compare I-DXd against physician's choice of therapy (topotecan, amrubicin, or lurbinectedin) as a second-line treatment.
• To determine if I-DXd improves outcomes, including overall survival and objective response rate, in this patient population.

Main Methods:

• IDeate-Lung02 is a global, randomized, open-label Phase 3 study involving approximately 540 patients.
• Eligible patients have relapsed SCLC, received one prior platinum-based therapy, and have an ECOG performance status of 0-1.
• Participants are randomized 1:1 to receive I-DXd (12 mg/kg IV every 3 weeks) or treatment of physician's choice.

Main Results:

• Primary endpoints include objective response rate (ORR) and overall survival (OS) assessed by blinded independent central review (BICR).
• Secondary endpoints encompass progression-free survival (PFS), duration of response, disease control rate, time to response, patient-reported outcomes, and safety.
• The study aims to establish the superiority of I-DXd over current standard second-line therapies.

Conclusions:

• The IDeate-Lung02 study will provide crucial data on the effectiveness of B7-H3-targeted therapy in relapsed SCLC.
• Findings will inform clinical practice regarding the use of ifinatamab deruxtecan as a second-line treatment option.
• This trial is critical for improving outcomes for patients with limited treatment alternatives in SCLC.